title: Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study.
abstract: To assess the effectiveness of intravitreal dexamethasone implants for treating postsurgical macular oedema (PSMO) including Irvine-Gass syndrome and determining the predictive factors of treatment response.
  
  
  
  Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. One hundred patients were included between April 2011 and June 2014, with a minimum of 1-year follow-up. Patients received dexamethasone implant 0.7 mg at baseline. Clinical characteristics, best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT) and intraocular pressure were measured at each visit. The main outcome measure was the change in BCVA (Early Treatment of Diabetic Retinopathy Study (ETDRS) letters: L). An analysis of predictive factors of treatment response is also provided.
  
  
  
  Mean improvement in BCVA was 9.6 (±10.6) L at month 6 and 10.3 (±10.7) L at month 12 (p<0.001). The proportion of eyes with gains in BCVA of 15 or more letters was 32.5% and 37.5% at months 6 and 12, respectively. The mean reduction in CSMT was 135.2 and 160.9 µm at months 6 and 12, respectively (p<0.001). Thirty-seven per cent of patients did not need a second injection after the first injection during follow-up. The presence of at least one PSMO risk factor decreases the probability of a gain in visual acuity (VA) ≥10 L (p=0.006). Initial VA ≤50 L at baseline and non-naïve status decrease the probability of having only one injection during follow-up (p=0.044).
  
  
  
  The significant gain in BCVA from baseline achieved at month 6 was maintained at month 12 after intravitreal injection of dexamethasone implant. Naïve status seems to be a good predictive factor of treatment response.
authors.affiliation: Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.|CNRS UMR 5510 Mateis, Villeurbanne, France.
authors.forename: David
authors.initials: D
authors.lastname: Bellocq
authors.affiliation: Department of Ophthalmology, Hôpital Foch, Suresnes, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Pierre-Kahn
authors.affiliation: Department of Ophthalmology, Nord Hospital, Aix Marseille University, Institut de Neurosciences de la Timone, CNRS/ UMR7289, Marseille, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Matonti
authors.affiliation: Department of Ophthalmology, Edouard Herriot Hospital, University of Lyon I, Institut de Biologie et Chimie des Protéines, CNRS/ UMR5086, Lyon, France.
authors.forename: Carole
authors.initials: C
authors.lastname: Burillon
authors.affiliation: Hospices Civils de Lyon, Service de Biostatistique, Lyon, France.|Laboratoire de Biométrie et Biologie Evolutive, CNRS, UMR 5558, Equipe Biostatistique-Santé, Villeurbanne, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Voirin
authors.affiliation: Department of Ophthalmology, Desgenettes military Hospital, University of Val de Grâce, Paris, France.
authors.forename: Corinne
authors.initials: C
authors.lastname: Dot
authors.affiliation: Department of Ophthalmology, XV XX Ophthalmic National Hospital Center, Paris, France.
authors.forename: Jad
authors.initials: J
authors.lastname: Akesbi
authors.affiliation: Department of Ophthalmology, University of Picardie Jules Verne, CHU Amiens Picardie -Site Sud D408 Amiens cedex 1 80054 . France. Center n° 86 of network EVICR-net, Amiens, France.
authors.forename: Solange
authors.initials: S
authors.lastname: Milazzo
authors.affiliation: Department of Ophthalmology, Saint Roch University Hospital, Nice Sophia Antipolis, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Baillif
authors.affiliation: Department of Ophthalmology, University Hospital, Toulouse, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Soler
authors.affiliation: Centre Ophtalmologique Maison Rouge, Strasbourg, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Wolff
authors.affiliation: Department of Ophthalmology, Fondation Rotschild, Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Scemama
authors.affiliation: Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.|CNRS UMR 5510 Mateis, Villeurbanne, France.
authors.forename: Ariane
authors.initials: A
authors.lastname: Malclès
authors.affiliation: Department of Ophthalmology, University Hospital of Nantes, Nantes, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Weber
authors.affiliation: Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.|CNRS UMR 5510 Mateis, Villeurbanne, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Kodjikian
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy; D012189:Retrospective Studies; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone
keywords: Drugs; Inflammation; Macula